Cargando…

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis

BACKGROUND: We performed a systematic review and meta-analysis to evaluate the risks of cardiac adverse events in solid tumor patients treated with monotherapy of immune checkpoint inhibitors (ICIs) or combined therapy of ICIs plus chemotherapy. METHODS: Eligible studies were selected through the fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Jiexuan, Tian, Ruyue, Ma, Yingjie, Zhen, Hongchao, Ma, Xiao, Su, Qiang, Cao, Bangwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190385/ https://www.ncbi.nlm.nih.gov/pubmed/34123795 http://dx.doi.org/10.3389/fonc.2021.645245

Ejemplares similares

Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature
por: Kang, Yan, et al.
Publicado: (2023)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors
por: Rose, Lynn M., et al.
Publicado: (2021)

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
por: Ouyang, Tao, et al.
Publicado: (2021)

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
por: Rapoport, Bernardo Leon
Publicado: (2019)

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
por: Hommes, Josefien W., et al.
Publicado: (2021)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis
por: Yang, Wenhan, et al.
Publicado: (2020)

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
por: Park, Robin, et al.
Publicado: (2020)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
por: Sebestyén, Enikő, et al.
Publicado: (2023)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
por: Hana, Caroline, et al.
Publicado: (2023)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis
por: Liu, Kang, et al.
Publicado: (2021)

Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis
por: Zou, Defang, et al.
Publicado: (2023)

Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers
por: Fernandez, Elvelyn R., et al.
Publicado: (2023)

Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events
por: Kadowaki, Hiroshi, et al.
Publicado: (2021)

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
por: Ellithi, Moataz, et al.
Publicado: (2020)

Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course
por: Jiang, Mengjie, et al.
Publicado: (2022)

Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
por: Fan, Yong, et al.
Publicado: (2021)

Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events
por: Zeng, Yanlin, et al.
Publicado: (2023)

Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis
por: Sun, Qian, et al.
Publicado: (2022)

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database
por: Cui, Chanjuan, et al.
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
por: Wang, Jingting, et al.
Publicado: (2022)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials
por: Zheng, Jianqing, et al.
Publicado: (2022)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
por: Chye, Adrian, et al.
Publicado: (2022)

Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis
por: Ederhy, Stéphane, et al.
Publicado: (2021)

Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis
por: Ma, Yan, et al.
Publicado: (2022)

A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy
por: Murakata, Yoshiko, et al.
Publicado: (2022)

Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis
por: Kiss, Igor, et al.
Publicado: (2022)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
por: Vani, Vanina, et al.
Publicado: (2020)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gk3tuhdcccjbc2rof24relfhma